ESMO | Physician's Weekly
Advertisement

ESMO

ESMO: Is KRAS Finally ’Druggable’?

Sotorasib results promising in phase 1 trial Results of a 129-patient phase I trial of sotorasib, an investigational small molecule agent that “selectively and irreversibly” targets KRASG12C, produced responses in...

Loading

Advertisement

For latest news and updates
Email-id is invalid